Miltenyi Bioindustry

Miltenyi Bioindustry is a globally active, full-service CDMO with over 25 years of experience in the cell and gene therapy space. It offers integrated development and manufacturing services for lentiviral vectors and cell therapies, supported by its proprietary CliniMACS platform technology. The company has a substantial track record, having manufactured over 700 GMP cell therapy batches and 400 GMP lentiviral vector batches for over 100 clinical trials. As a private division of Miltenyi Biotec, it benefits from deep technological roots and a mission to improve the availability and affordability of advanced therapies.

Proprietary CliniMACS platform for automated, closed-system cell processing (including CliniMACS Prodigy, Electroporator, Formulation Unit) and a scalable lentiviral vector manufacturing platform.

Miltenyi Bioindustry competes with large, diversified CDMOs (e.g., Lonza, Catalent, Thermo Fisher/Patheon) and specialized cell/gene therapy CDMOs (e.g., Oxford Biomedica, Cell Therapies, Charles River's Cognate). Its key differentiator is the vertical integration with its own widely adopted CliniMACS manufacturing technology, which creates a captive ecosystem and significant switching costs for clients already using its platforms.